Improvement of Clopidogrel Hypo-Responsiveness by Cilostazol Addition to the Dual Antiplatelet Therapy in PCI Patients Carrying CYP2C19 Gene Polymorphism

被引：0
|
作者：
Tanigawa, Takashi [1 ]
Nakata, Tomoyuki [1 ]
Ito, Masaaki [1 ]
Nishikawa, Masakatsu [1 ]
机构：
[1] Mie Univ Hosp, Tsu, Mie, Japan
来源：
CIRCULATION | 2010年 / 122卷 / 21期
关键词：
Antiplatelet drugs; Platelet receptor blockers; Intervention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14257
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
    Gurbel, Paul A.
    Shuldiner, Alan R.
    Bliden, Kevin P.
    Ryan, Kathaleen
    Pakyz, Ruth E.
    Tantry, Udaya S.
    AMERICAN HEART JOURNAL, 2011, 161 (03) : 598 - 604
  • [32] CYP2C19 GENETIC POLYMORPHISM ON CLOPIDOGREL RESPONSE IN VIETNAMESE PATIENTS WITH CORONARY STENTING
    Kim, N. T.
    Nguyen, M. N. T.
    Do, D. L.
    Nguyen, Q. H.
    Nguyen, T. T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E83 - E84
  • [33] Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy
    Yu Wu
    Yilun Zhou
    Yuesong Pan
    Xingquan Zhao
    Liping Liu
    David Wang
    Chunxue Wang
    Hao Li
    S. Claiborne Johnston
    Xia Meng
    Yilong Wang
    Yongjun Wang
    The Pharmacogenomics Journal, 2018, 18 : 713 - 720
  • [34] Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients
    Eva Viveros, Martha
    Arean, Carlos
    Gutierrez, Sergio
    Vazquez, Soledad
    Humberto Cardiel, Mario
    Taboada, Alejandra
    Marin, Gissela
    Solorio, Ruben
    Garcia, Nalley
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2016, 86 (04): : 297 - 304
  • [35] Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy
    Wu, Yu
    Zhou, Yilun
    Pan, Yuesong
    Zhao, Xingquan
    Liu, Liping
    Wang, David
    Wang, Chunxue
    Li, Hao
    Johnston, S. Claiborne
    Meng, Xia
    Wang, Yilong
    Wang, Yongjun
    PHARMACOGENOMICS JOURNAL, 2018, 18 (06): : 713 - 720
  • [36] Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes
    Chen, Keguang
    Zhang, Rui
    Liu, Huanjun
    Guo, Xi
    Li, Pingli
    Liu, Xuehong
    CLINICAL LABORATORY, 2016, 62 (09) : 1773 - 1780
  • [37] The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism
    Bockeria, O. L.
    Kudzoeva, Z. F.
    Shvarts, V. A.
    Koasari, A. K.
    Donakanyan, S. A.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (05) : 47 - 54
  • [38] Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy
    Bergmeijer, Thomas O.
    Vos, Gerrit J. A.
    Claassens, Daniel M. F.
    Janssen, Paul W. A.
    Harms, Remko
    van der Heide, Richard
    Asselbergs, Folkert W.
    ten Berg, Jurrien M.
    Deneer, Vera H. M.
    PHARMACOGENOMICS, 2018, 19 (07) : 621 - 628
  • [39] Frequency of CYP2C19 Gene Polymorphism in Stented Patients: Review
    Taizhanova, Dana
    Toleuova, Aliya
    Bodaubai, Roza
    Kalimbetova, Akerke
    Kurmanova, Aigul
    Turmuhambetova, Anar
    Babenko, Dmitriy
    Chesca, Antonella
    PROCEEDINGS OF THE 35TH BALKAN MEDICAL WEEK, 2018, : 156 - 159
  • [40] Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome
    Jirungda, Sornsith
    Pussadhamma, Burabha
    Komanasin, Nantarat
    Senthong, Vichai
    Leuangwatthananon, Wit
    CORONARY ARTERY DISEASE, 2020, 31 (03) : 266 - 272
12345